Clinical Trials | December 29, 2025
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The primary goal of the collaboration is joint research into trending and next-generation molecules
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
Subscribe To Our Newsletter & Stay Updated
